Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Brain Cancer: early-phase trial registry
20 of 48 indexed Brain Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #297 of 28,707 conditions by registered trial count.
48 US clinical trials · 20 currently recruiting · #297 of 28,707 conditions by registered trial count
Brain Cancer: 48 US clinical trials tracked, 20 recruiting.
Brain Cancer is the subject of 48 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Northwell Health, running 7 of these trials.
Enrollment posture brief
Registry condition brain-cancer
OPEN 20 | RECR 42% | LATE 2 | EARLY 27 | RANK #297 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia in Remission (42% recruiting · 12 trials)
Brain Cancer lists 20 open slots (42% of 48 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Brain Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Brain Cancer is recruiting above its size-band peers.
20 of 48 indexed trials (41.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Brain Cancer trials is spread across many organizations.
Northwell Health accounts for 7 of 48 trials (14.6%). 26 distinct sponsors appear on at least one study for this condition label.
-
Most Brain Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 48 trials that report a genuine target (sentinel values excluded). 33 of those (68.8%) plan for fewer than 100 participants.
-
Brain Cancer research is mostly interventional.
38 interventional and 10 observational studies make up this index (79.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
48 total, page 1 of 1
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
UMC Utrecht
NCT04075305
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Adela
NCT05366881
Wearable Devices and Biomarkers Project (Healthiomics)
CureScience
NCT05106725
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
NCT05271240
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Baptist Health South Florida
NCT06991101
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics
NCT07326566
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00870129
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
Dartmouth-Hitchcock Medical Center
NCT06930846
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
National Cancer Institute (NCI)
NCT07374692
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Northwell Health
NCT03213002
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
Baptist Health South Florida
NCT06048094
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
NCT02800486
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Northwell Health
NCT02861898
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Northwell Health
NCT05954858
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
NCT06058988
Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
David W. Roberts
NCT02691923
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Baptist Health South Florida
NCT04689048
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Baptist Health South Florida
NCT05554302
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Henry Ford Health System
NCT05686798
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT05979064
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
NCT05179824
Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
Memorial Sloan Kettering Cancer Center
NCT02375841
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
NCT04899908
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
NCT04478279
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
Medical College of Wisconsin
NCT05023434
Observational Trial of the Impact of Radiation Dose in Children With Brain and Skull Base Tumors.
Baptist Health South Florida
NCT03972514
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Dana-Farber Cancer Institute
NCT02852655
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
Memorial Sloan Kettering Cancer Center
NCT03465618
Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM
Northwell Health
NCT03630289
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
Memorial Sloan Kettering Cancer Center
NCT01892397
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
National Cancer Institute (NCI)
NCT02851706
Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue
University of Michigan
NCT00723463
Randomized Trial Comparing Radiosurgery With vs Without Whole Brain Radiotherapy
M.D. Anderson Cancer Center
NCT00548756
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
NCT01067469
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
M.D. Anderson Cancer Center
NCT00504660
Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy
Washington University School of Medicine
NCT05427214
Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
Y-mAbs Therapeutics
NCT01502917
(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy
National Cancer Institute (NCI)
NCT00001807
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT00871923
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Duke University
NCT02457715
Imaging Brain Tumors With FACBC and Methionine
Memorial Sloan Kettering Cancer Center
NCT00597246
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Katy Peters, MD, PhD
NCT02193347
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Andrew B Lassman, MD
NCT01257594
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Stanford University
NCT00946673
Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
Stanford University
NCT00185861
Phase I, Open Label, Single Center Safety Study of [F-18]FLT
Siemens Molecular Imaging
NCT00553748
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
Monteris Medical
NCT00747253
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
Memorial Sloan Kettering Cancer Center
NCT04173104
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 10 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Brain Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Brain Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Brain Cancer page
48 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 20 Brain Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Northwell Health sponsors the most Brain Cancer trials on record, review their full trial history before evaluating a specific study. See Northwell Health's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Brain Cancer condition card totals 48 registered trials; most-linked intervention Temozolomide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.